PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.

Amit AgarwalSaphalta BaghmarChandragouda DodagoudarSuhail QureshiAseem KhuranaVikas VaibhavGuresh Kumar

Published in: JCO global oncology (2021)

This is the first study from India evaluating PARPi in platinum-resistant ovarian cancer. This study suggests that PARPi is a viable treatment option in patients with PROC with gBRCAm. This should be further evaluated in randomized clinical trial.

Keyphrases

dna damage
replacement therapy
combination therapy